Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > REGULATORY
REGULATORY
- Discussions on Cost-Effective Assessments Are for Preserving National Health Insurance System: Parliamentary Secretary Umemura
October 11, 2012
- Results of Paper-Based Inspection of Japan’s Application for Membership in PIC/S to Be Reported Next May
October 10, 2012
- Dr Takenaka Tapped as NIBIO Advisor, Committed to Creation of Drug Discovery Network
October 9, 2012
- Senior Vice Minister of Health Sakurai Stresses Need to Rebuild Ties with JMA
October 9, 2012
- Health Minister Mitsui Hopes to Ban All Forms of Dispensing Point Services Including Those Using Credit Cards
October 9, 2012
- MHLW to Request Development of 5 Drugs/Indications Determined to Have Unmet Medical Needs
October 5, 2012
- Ministry-Wide Discussions on Generics Necessary: Parliamentary Secretary Umemura
October 4, 2012
- Senior Vice Minister Sakurai Calls for Industry-Growth Perspective on Long-Listed Drug Pricing
October 4, 2012
- MHLW Issues Notification for Precautions in Use of Methapain
October 4, 2012
- Minister of Health Mitsui Sees Need for Cross-Agency Efforts to Promote New Drug Development
October 4, 2012
- MHLW to Enhance Drug Review System to Eliminate Application Lag: PFSB Director Gen. Ebata
October 3, 2012
- Committee to Discuss Basic Policy for Improving Safety and Supply of Blood Products for Its Revision in FY2013
October 3, 2012
- MHLW Issues Improvement Order to Benesis Due to Tampering of Packaging Boxes after Permitting Shipment
October 2, 2012
- Pharmacist Mitsui Becomes Health Minister, Industry Hails Appointment
October 2, 2012
- MHLW Approves 26 Products Including Novartis’s Seebri
October 2, 2012
- Perpetuation of Premium for New Drug Development Will Depend on Convincing Data: HIB Director General Kikura
October 2, 2012
- Study Group Outlines Plan to Establish Palliative Care Centers at Designated Cancer Treatment Alliance Hospitals
October 1, 2012
- MHLW Reports Package Insert Revisions for Elplat
September 28, 2012
- Price Gap between Long-Listed Products, Generics Should Be Retained: Mr Chikazawa of MHLW
September 28, 2012
- MHLW Asks FPMAJ to Revise Precaution Section of Package Inserts for 13 APIs Including Diclofenac
September 28, 2012
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…